



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>5</sup> :</b> C07H 15/12, 17/00, C12Q 1/68 C12P 19/34, C12N 15/00 A01N 43/04, A61K 31/70	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 92/03456</b>  <b>(43) International Publication Date:</b> 5 March 1992 (05.03.92)
<b>(21) International Application Number:</b> PCT/US91/05815  <b>(22) International Filing Date:</b> 14 August 1991 (14.08.91)  <b>(30) Priority data:</b> 568,366 16 August 1990 (16.08.90) US  <b>(60) Parent Application or Grant</b> (63) Related by Continuation US 568,366 (CIP) Filed on 16 August 1990 (16.08.90)  <b>(71) Applicant (for all designated States except US):</b> ISIS PHARMACEUTICALS, INC. [US/US]; 2280 Faraday Avenue, Carlsbad, CA 92008 (US).	<b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only) :</b> ANDERSON, Kevin, P. [US/US]; 2772 La Gran Via, Carlsbad, CA 92009 (US). DRAPER, Kenneth, G. [US/US]; 445 Richmond Park West, Apartment 322B, Richmond, OH 44143 (US).  <b>(74) Agents:</b> CALDWELL, John, W. et al.; Woodcock Wash- burn Kurtz Mackiewicz & Norris, One Liberty Place, 46th Floor, Philadelphia, PA 19103 (US).  <b>(81) Designated States:</b> AT (European patent), AU, BE (Euro- pean patent), BR, CA, CH (European patent), DE (Eu- ropean patent), DK (European patent), ES (European patent), FI, FR (European patent), GB (European pa- tent), GR (European patent), HU, IT (European patent), JP, KR, LU (European patent), NL (European patent), NO, SE (European patent), US.  <b>Published</b> <i>With international search report.</i>	

**(54) Title:** OLIGONUCLEOTIDES FOR MODULATING THE EFFECTS OF CYTOMEGALOVIRUS INFECTIONS**(57) Abstract**

Compositions and methods for modulating the effects of cytomegalovirus (CMV) infections are disclosed, comprising contacting CMV mRNA with an oligonucleotide or oligonucleotide analog which can bind with at least portions of the CMV RNA. In accordance with the preferred embodiments, oligonucleotides or oligonucleotide analogs are designed to bind with portions of the CMV mRNAs which code for the IE1, IE2 or DNA polymerase proteins. In accordance with a preferred embodiment, methods of treatment of human cytomegalovirus are disclosed.

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	ES	Spain	MC	Madagascar
AU	Australia	FI	Finland	ML	Mali
BB	Barbados	FR	France	MN	Mongolia
BE	Belgium	GA	Gabon	MR	Mauritania
BF	Burkina Faso	GB	United Kingdom	MW	Malawi
BG	Bulgaria	GN	Guinea	NL	Netherlands
BJ	Benin	GR	Greece	NO	Norway
BR	Brazil	HU	Hungary	PL	Poland
CA	Canada	IT	Italy	RO	Romania
CF	Central African Republic	JP	Japan	SD	Sudan
CG	Congo	KP	Democratic People's Republic of Korea	SE	Sweden
CH	Switzerland	KR	Republic of Korea	SN	Senegal
CI	Côte d'Ivoire	LI	Liechtenstein	SU <sup>+</sup>	Soviet Union
CM	Cameroon	LK	Sri Lanka	TD	Chad
CS	Czechoslovakia	LU	Luxembourg	TG	Togo
DE <sup>+</sup>	Germany	MC	Monaco	US	United States of America
DK	Denmark				

+ Any designation of "SU" has effect in the Russian Federation. It is not yet known whether any such designation has effect in other States of the former Soviet Union.

- 1 -

## OLIGONUCLEOTIDES FOR MODULATING THE EFFECTS OF CYTOMEGALOVIRUS INFECTIONS

### FIELD OF THE INVENTION

This invention relates to the design and  
5 synthesis of antisense oligonucleotides which can be  
administered to inhibit the replication of cytomegalovirus  
and treat cytomegalovirus infections. These compounds can  
be used either prophylactically or therapeutically to  
reduce the severity of disease caused by cytomegaloviruses.  
10 Oligonucleotides and oligonucleotide analogs which are  
specifically hybridizable with RNA targets are described.

### BACKGROUND OF THE INVENTION

Cytomegaloviruses (CMV's) are ubiquitous in  
nature and are the most common causes of intrauterine  
15 infection. Congenital infection is common in newborns of  
infected mothers. In some populations, as much as 10% of  
children display perinatal infections. In a small  
percentage of newborns, the infection is virulent,  
involving multiple organs. Pronounced involvement of the  
20 reticuloendothelial and central nervous system is typical;  
and the infection is a major cause of mental retardation.  
Careful testing demonstrates that as many as 50% of  
severely, prenatally infected adults may display  
neuropsychiatric disease or deafness. Although extraneural  
25 organs are usually spared chronic morbidity, the virus can  
be detected in the kidney for years.

In the adult, cytomegalovirus-induced  
mononucleosis is a lingering illness that causes  
significant morbidity. If it occurs in immunosuppressed

### SUBSTITUTE SHEET

- 2 -

patients, the disease is more severe, and it may be complicated by other infectious pathogens which may be fatal. Cytomegalovirus retinitis is a severe problem in immunosuppressed patients that often leads to blindness.

5 Immunosuppressed patients are also very susceptible to CMV pneumonitis, which is one of the most lethal of human viral diseases. Although cytomegalovirus may play a role in the progression of HIV infection to AIDS by stimulating the transcription of the HIV long terminal repeats (LTR) in  
10 non-transformed co-infected T cells, histologic examination of adrenals and brains from AIDS patients has suggested that the adrenalitis, encephalitis and peripheral neuropathy were caused by CMV infection.

CMV is considered to be an oncogenic virus. In  
15 vitro, CMV can transform cells and stimulate growth. Both human and non-human cells can undergo transformation when incubated with CMV. Transformed cells contain CMV antigens that are oncogenic when inoculated into appropriate animals. Moreover, oncogenic potential has been associated  
20 with specific segments of the CMV genome.

Human CMV is a large, enveloped herpesvirus whose genome consists of a double-stranded DNA molecule which is approximately 240,000 nucleotides in length. This genome is the most complex of all DNA viruses and is approximately  
25 50% larger than the genome of herpes simplex virus (HSV). Intact viral DNA is composed of contiguous long (L) and short (S) segments, each of which contains regions of unique DNA sequence flanked by homologous regions of repetitive sequence. As a group, the human CMV isolates  
30 share at least 80% sequence homology, making it nearly impossible to classify cytomegaloviruses into subgroups or subtypes, although variations in the restriction endonuclease patterns of various CMV DNA preparations are identifiable in epidemiologically unrelated strains. The  
35 DNA of the prototypic strain of CMV (AD 169) has been sequenced and reported to contain a conservative estimate of 175 unique translational open reading frames (ORFs). A

**SUBSTITUTE SHEET**

- 3 -

number of the predicted CMV gene products show homology to other human herpesvirus gene products. At least 42 ORFs encode putative glycoproteins and several of the CMV ORFs putatively encode proteins with amino acid homology to human opsin receptor proteins.

In permissive human fibroblasts, CMV gene expression is regulated by a cascade of genetic events that act at both the transcriptional and translational levels. CMV gene expression can be divided into three phases which resemble those of HSV defined as the immediate early (IE), early and late periods. Following adsorption, penetration and uncoating of the virus, a group of viral transcripts, immediate early messenger RNAs (IE mRNAs) are synthesized within 1-4 hours even in the presence of translational inhibitors such as cycloheximide. In the normal course of infection, the IE mRNAs are translated and their protein products are instrumental in the onset of early transcriptional events. At least 4 proteins are synthesized from IE mRNAs; of these, one is a glycoprotein. The IE1 and IE2 proteins are transcriptional activating factors for other CMV genes and the IE3 protein encompasses a region of the CMV genome which can transform NIH 3T3 cells *in vitro*. Early proteins are encoded by the mRNAs which are synthesized prior to viral DNA synthesis. A number of the early proteins play a role in nucleotide metabolism and DNA synthesis in the infected cell. After the onset of viral DNA synthesis, the transcription of the late mRNAs is maximal and probably reflects a template abundancy requirement similar to that observed for analogous HSV mRNAs. The late CMV proteins include the glycoprotein constituents of the viral envelope, the viral capsid proteins and other proteins which are necessary for assembly or structural integrity of the mature CMV particle and/or egress of the assembled virion from the infected cell. In addition to the transcriptional controls operant upon CMV gene expression, examples of post-transcriptional controls are known to influence the appearance of some CMV

**SUBSTITUTE SHEET**

- 4 -

proteins. Splicing of mRNAs is more common than observed in HSV gene expression and the nucleotide sequence composition of the 5' nontranslated region in the cognate mRNA is reported to influence the synthesis of at least one  
5 early CMV protein.

Effective therapy for CMV has not yet been developed despite studies on a number of antivirals. Interferon, transfer factor, adenine arabinoside (Ara-A), acycloguanosine (Acyclovir, ACV) and certain combinations  
10 of these drugs have been ineffective in controlling CMV infection. Based on preclinical and clinical data, foscarnet (PFA) and ganciclovir (DHPG) show limited potential as antiviral agents. PFA treatment has resulted in the resolution of CMV retinitis in five AIDS patients.  
15 DHPG studies have shown efficacy against CMV retinitis or colitis. DHPG seems to be well tolerated by treated individuals, but the appearance of a reversible neutropenia, the emergence of resistant strains of CMV upon long-term administration, and the lack of efficacy against  
20 CMV pneumonitis limit the long term applications of this compound. The development of more effective and less-toxic therapeutic compounds and methods is needed for both acute and chronic use.

Classical therapeutics has generally focused upon  
25 interactions with proteins in efforts to moderate their disease causing or disease potentiating functions. Such therapeutic approaches have failed for cytomegalovirus infections. The present invention is directed to an alternative approach to the treatment of such infections,  
30 the antisense inhibition of cytomegalovirus gene expression through the mediation of oligonucleotides or oligonucleotide analogs.

Antisense methodology is the complementary hybridization of relatively short oligonucleotides to  
35 single-stranded mRNA or single-stranded DNA, or even double stranded DNA, such that the normal, essential functions of these intracellular nucleic acids are disrupted.

SUBSTITUTE SHEET

- 5 -

Hybridization is the sequence specific hydrogen bonding of oligonucleotides to Watson-Crick base pairs of RNA or single stranded DNA. Such base pairs are said to be complementary to one another.

5           The events which disrupt nucleic acid function are discussed by Cohen in *Oligonucleotides: Antisense Inhibitors of Gene Expression*, CRC Press, Boca Raton FL, (1989) who proposes two possible types of terminating events. The first, hybridization arrest, denotes a  
10 terminating event in which the oligonucleotide inhibitor binds to the target nucleic acid and thus prevents, by simple steric hindrance, the binding of essential proteins, most often ribosomes, to the nucleic acid. Methyl phosphonate oligonucleotides; P. S. Miller & P.O.P. Ts'0,  
15 *Anti-Cancer Drug Design*, Vol. 2, pp. 117-128 (1987); and  $\alpha$ -anomer oligonucleotides, Cohen J.S. ed., *Oligonucleotides: Antisense Inhibitors of Gene Expression*, CRC Press, Boca Raton FL (1989) are two of the most extensively studied antisense agents which are thought to  
20 disrupt nucleic acid function by hybridization arrest.

A second type of terminating event for antisense oligonucleotides involves enzymatic cleavage of the targeted RNA by intracellular RNase H. The oligonucleotide or oligonucleotide analog, which must be of the deoxyribo  
25 type, hybridizes with the targeted RNA and this duplex activates the RNase H enzyme to cleave the RNA strand, thus destroying the normal function of the RNA. Phosphorothioate oligonucleotides are a prominent example of an antisense agent which operates by this type of  
30 terminating event.

Considerable research is being directed to the application of oligonucleotides and oligonucleotide analogs as antisense agents for therapeutic purposes. Applications of oligonucleotides as diagnostics, research reagents, and  
35 potential therapeutic agents require that the oligonucleotides or oligonucleotide analogs be synthesized in large quantities, be transported across cell membranes

SUBSTITUTE SHEET

- 6 -

or taken up by cells, appropriately hybridize to targeted RNA or DNA, and subsequently terminate or disrupt nucleic acid function. These critical functions depend on the initial stability of oligonucleotides towards nuclease  
5 degradation.

Oligonucleotides and analogs modified to exhibit resistance to nucleases, to activate the RNase H terminating event, and to hybridize with appropriate strength and fidelity to targeted RNA (or DNA) are greatly  
10 desired for antisense oligonucleotide diagnostics, therapeutics and research with cytomegaloviruses.

#### OBJECTS OF THE INVENTION

It is an object of this invention to provide oligonucleotides and oligonucleotide analogs which are  
15 capable of hybridizing with messenger RNA of cytomegalovirus to inhibit the function of the messenger RNA.

It is a further object to provide oligonucleotides and analogs which can modulate the  
20 expression of cytomegalovirus through antisense interaction with messenger RNA of the virus.

Yet another object of this invention is to provide methods of diagnostics and therapeutics for  
cytomegalovirus in animals.

25 Methods, materials and kits for detecting the presence or absence of cytomegalovirus in a sample suspected of containing it are further objects of the invention.

Novel oligonucleotides and oligonucleotide  
30 analogs are other objects of the invention.

These and other objects will become apparent to persons of ordinary skill in the art from a review of the instant specification and appended claims.

#### SUMMARY OF THE INVENTION

35 In accordance with the present invention, methods of modulating the effects of cytomegalovirus infection are provided. Oligonucleotides and oligonucleotide analogs



- 7 -

having a sequence of nucleotide bases specifically hybridizable with a selected sequence of a cytomegalovirus RNA are provided. It has been determined that targeting cytomegalovirus mRNA coding for the IE1, IE2, or DNA polymerase proteins is a key to the effective antisense therapy with these oligonucleotides or oligonucleotide analogs. ~~Methods for treating disease states by administering oligonucleotides or oligonucleotide analogs, either alone or in combination with a pharmaceutically acceptable carrier, to animals suspected of having cytomegalovirus infections are provided.~~

This relationship is commonly denoted as "antisense." The oligonucleotides and oligonucleotide analogs are able to inhibit the function of RNA -- either its translation into protein, its translocation into the cytoplasm, or any other activity necessary to its overall biological function. The failure of the RNA to perform all or part of its function results in failure of a portion of the genome controlling the normal life cycle of the virus.

It has now been found that oligonucleotides or oligonucleotide analogs can be designed especially for cytomegalovirus infections which are effective in diminishing the infection. It is preferred that oligonucleotides and analogs have between about 5 and about 50 nucleic acid base units. It is preferred that the oligonucleotide or analog be specifically hybridizable with mRNA coding for the CMV IE1, IE2, or DNA polymerase proteins. The oligonucleotide analog may be modified to reduce nuclease resistance and to increase their efficacy.

In accordance with preferred embodiments, the mRNA is interfered with to an extent sufficient to inhibit CMV replication. Thus, oligonucleotides and oligonucleotide analogs which are capable of interacting with portions of CMV mRNA are comprehended. Animals suspected of having the disease are contacted with an oligonucleotide or oligonucleotide analog made in accordance with this invention. In particular, the present

- 8 -

invention is believed to be effective in the treatment of cytomegalovirus infections, either prophylactically or therapeutically.

#### DESCRIPTION OF THE FIGURES

5                Figure 1 is a bar graph showing the antiviral activity of oligonucleotides 2725 through 2890 against cytomegalovirus.

              Figure 2 is a bar graph showing the antiviral activity of oligonucleotides 2891 through 3300 against  
10 cytomegalovirus.

              Figure 3 is a line graph showing antiviral effects of eight oligonucleotides at doses from 0.01 to 10  $\mu\text{M}$ .

              Figure 4 is a line graph showing antiviral  
15 effects of three oligonucleotides at doses from 0.1 to 10  $\mu\text{M}$ .

#### DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS

Antisense oligonucleotides hold great promise as therapeutic agents for the treatment of many human  
20 diseases. Oligonucleotides specifically bind to the complementary sequence of either pre-mRNA or mature mRNA, as defined by Watson-Crick base pairing, inhibiting the flow of genetic information from DNA to protein. Numerous recent studies have documented the utility of antisense  
25 oligonucleotides as biochemical tools for studying target proteins. Rothenberg et. al., *J. Natl. Cancer Inst.* 81:1539-1544 (1989); Zon, G. *Pharmaceutical Res.*, 5:539-549 (1987). Because of recent advances in oligonucleotide chemistry, synthesis of nuclease-resistant  
30 oligonucleotides, and availability of types of oligonucleotide analogs which exhibit enhanced cell uptake, it is now possible to consider the use of antisense oligonucleotides as a novel form of therapeutics.

For therapeutics, an animal suspected of having a  
35 cytomegalovirus infection is treated by administering oligonucleotides or oligonucleotide analogs in accordance with this invention. Persons of ordinary skill can easily

- 9 -

determine optimum dosages, dosing methodologies and repetition rates. Such treatment is generally continued until either a cure is effected or a diminution in the disease state is achieved.

5           It is to be expected that differences in the DNA of cytomegalovirus from different species and from different types within a species exist. Thus, it is believed, for example, that the regions of the various cytomegalovirus species serve essentially the same function  
10 for the respective species and that interference with expression of the genetic information will afford similar results in the various species. This is believed to be so even though differences in the nucleotide sequences among the species doubtless exist.

15           Accordingly, nucleotide sequences set forth in the present specification will be understood to be representational for the particular species being described. Homologous or analogous sequences for different species of cytomegalovirus are specifically contemplated as  
20 being within the scope of this invention.

The present invention employs oligonucleotides and oligonucleotide analogs for use in antisense inhibition of the function of cytomegalovirus RNA. In the context of this invention, the term "oligonucleotide" refers to a  
25 polynucleotide formed from naturally occurring bases and pentofuranosyl groups joined by native phosphodiester bonds. This term effectively refers to naturally-occurring species or synthetic species formed from naturally-occurring subunits or their close homologs.

30           "Oligonucleotide analog," as that term is used in connection with this invention, refers to moieties which function similarly to oligonucleotides but which have non-naturally occurring portions. Thus, oligonucleotide analogs may have altered sugar moieties or inter-sugar  
35 linkages. Exemplary among these are the phosphorothioate and other sulfur-containing species which are known for use in the art. In accordance with some preferred embodiments,

- 10 -

at least some of the phosphodiester bonds of the oligonucleotide have been substituted with a structure which functions to enhance the ability of the compositions to penetrate into the region of cells where the RNA or DNA whose activity to be modulated is located. It is preferred that such substitutions comprise phosphorothioate bonds, methyl phosphonate bonds, or short chain alkyl or cycloalkyl structures. In accordance with other preferred embodiments, the phosphodiester bonds are substituted with other structures which are, at once, substantially non-ionic and non-chiral, or with structures which are chiral and enantiomerically specific. Persons of ordinary skill in the art will be able to select other linkages for use in practice of the invention.

Oligonucleotide analogs may also include species which include at least some modified base forms. Thus, purines and pyrimidines other than those normally found in nature may be so employed. Similarly, modifications on the pentofuranosyl portions of the nucleotide subunits may also occur as long as the essential tenets of this invention are adhered to.

Such analogs are best described as being functionally interchangeable with natural oligonucleotides (or synthesized oligonucleotides along natural lines), but which have one or more differences from natural structure. All such analogs are comprehended by this invention so long as they function effectively to hybridize with cytomegalovirus RNA. The oligonucleotides and oligonucleotide analogs in accordance with this invention preferably comprise from about 3 to about 50 nucleic acid base units. It is more preferred that such oligonucleotides and analogs comprise from about 8 to 25 nucleic acid base units, and still more preferred to have from about 12 to 25 nucleic acid base units. As will be appreciated, a nucleic acid base unit is a base-sugar combination suitably bound to adjacent nucleic acid base unit through phosphodiester or other bonds.

SUBSTITUTE SHEET

- 11 -

The oligonucleotides and analogs used in accordance with this invention may be conveniently and routinely made through the well-known technique of solid phase synthesis. Equipment for such synthesis is sold by several vendors including Applied Biosystems. Any other means for such synthesis may also be employed, however the actual synthesis of the oligonucleotides are well within the talents of the routineer. It is also well known to use similar techniques to prepare other oligonucleotide analogs such as the phosphorothioates and alkylated derivatives.

In accordance with this invention, persons of ordinary skill in the art will understand that messenger RNA includes not only the information to encode a protein using the three letter genetic code, but also associated ribonucleotides which form a region known to such persons as the 5'-untranslated region, the 3'-untranslated region, and intron/exon junction ribonucleotides. Thus, oligonucleotides and oligonucleotide analogs may be formulated in accordance with this invention which are targeted wholly or in part to these associated ribonucleotides as well as to the informational ribonucleotides. In preferred embodiments, the oligonucleotide or analog is specifically hybridizable with a transcription initiation site, a translation initiation site, an intron/exon junction or sequences in the 5'- or 3'-untranslated region.

The HCMV genome is the most complex of the herpes viruses in terms of its genomic structure. Replication-defective mutants of HCMV have only been isolated for two viral genes, the immediate early complex (IE1 or IE2) and the DNA polymerase. These genes are known to play major roles in HCMV gene expression. They have been selected as primary targets for antisense compound design. Secondary target genes for the design of therapeutic antisense oligonucleotides and analogs have been selected by analogy to genes of herpes simplex virus. Such genes have been determined to be essential for herpes simplex virus

SUBSTITUTE SHEET

- 12 -

replication and/or sensitive to antisense inhibition. Four gene products of herpes simplex virus which have recently shown to be sensitive to antisense inhibition are the virion tegument protein (UL48), the two proteins  
5 constituting the ribonucleotide reductase enzyme (UL39,40) and a virion phosphotransferase (UL13). Other herpes simplex virus genes which are currently being studied are the auxiliary DNA replication enzymes (UL5, 8, 9, 29, 42, 52) and the major capsid protein (UL36). HCMV encodes  
10 proteins which have been identified as potentially analogous in function to each of these herpes simplex virus proteins; these genes have been selected to serve as secondary targets in connection with this invention.

The molecular biology of immediate early  
15 transcription in HCMV has been as well elucidated as that of any transcriptional unit in the eucaryotic cell. Briefly, synthesis of the major immediate early transcript (IE1) is controlled by a number of repeat units 5' of the mRNA cap site. These repeats are responsive to a number of  
20 transcriptional response molecules known to operate in cell-specific and differentiation specific manners. The IE1 mRNA is an abundant RNA which is 1.9 kb in length and encodes a protein which migrates with an apparent molecular weight of 72 kDa on PAGE-SDS. This protein has been found  
25 in virions and controls the expression of itself as well as that of the IE2 gene product. At the initial phase of immediate early transcription, only IE1 mRNA is synthesized by the cellular RNA polymerase. A small amount of IE2 mRNA is made by processing of the IE1 mRNA during this early  
30 time of infection. Over time, levels of IE1 protein accumulate and bind the promoter region of the IE1 gene, repressing further transcription of the IE1 mRNA and allowing a weaker downstream promoter for the IE2 gene to control further synthesis of IE2 mRNA. It has been  
35 proposed that the IE1 gene product may serve to boost viral transcription during a productive infection and alternatively to activate viral gene expression from the latent state. The observation of cell-type and differentiation or hormonal responsive elements in the

promoter of the IE1 gene are consistent with this proposition. The IE2 protein is capable of transcriptionally activating many of the HCMV early and late genes in a manner similar to other known transactivating proteins of cellular and viral origin. Thus, the IE2 protein is believed to be one of the master switches for HCMV gene expression. The other controlling switch of CMV genes is the DNA polymerase protein. Transcription of the late viral genes operates at very low levels until the onset of viral DNA replication, after which the late genes are activated by an increased template availability. The exact molecular condition which is operant in this enhanced template availability is unclear, but the presence of the viral DNA polymerase and replication of the genome are essential requirements for the observed effect.

The selected targets within the mRNA sequences include regions of the mRNA which are known to control mRNA stability, processing and/or translational efficiency. These target sites include the 5' cap regions and translation initiation control regions. The target sequences for the IE1, IE2, and DNA polymerase genes are set forth in Table 1:

TABLE 1

25 **TARGET SEQUENCES FOR CYTOMEGALOVIRUS  
Oligonucleotide SYNTHESIS**

	TARGET GENE	TARGET REGION	TARGET DNA SEQUENCE
	DNA POLYMERASE	mRNA CAP SITE	GGACCGGGACCACCGTCGTC
	DNA POLYMERASE	AUG REGION	GTCCGCTATGTTTTCAACCC
30	DNA POLYMERASE	CONSERVED AA (717-732)	CCTTCATCATCATGGCCCAC
	DNA POLYMERASE	CONSERVED AA (905-914)	GGCGCGGGTCATCTACGGGAC
35	DNA POLYMERASE	CMV INSERTION (608-697)	CCGCTGTGCCCCGGCGACGCGG CCGCCCTTGCAATCTGCGCCG GGCGTTTCACCCGGCTCCGGC
	DNA POLYMERASE	(1109-1159)	GCGCCCGGTGTCCGGACGGCG CCGCCGGCGTGTTTCCCGGT

			CCGGCAAAGAAGAGGGCGCGG
	IE1	mRNA CAP SITE	GTGAACCGTCAGATCGCCTGG
	IE1	AUG REGION	CTTGACACGATGGAGTCCTC
	IE1	I/E-1	GCCAAGAGTGACGTAAGTACC
5	IE1	I/E-2	GTCTTTTCTGCAGTCACCGTC
	IE1	I/E-3	CAAGGTGCCACGGTACGTGTC
	IE1	I/E-4	CATGTGTTTAGGCCCGAGAC
	IE1	I/E-5	GGCAGAACTCGGTAAGTCTG
	IE1	I/E-6	CCTCCTCTACAGTCAAACAG
10	IE2	AUG/CAP SITE	GCGCCTATCATGCTGCCCTC
	IE2	AUG REGION	GCTCTCCCAGATGAACCACCC
	IE2	I/E-1	CAAGATTGACGAGGTGAGCCG
	IE2	I/E-2	CCCAAACAGGTCATGGTGCGC
	IE2	NUC SIG-1	GCGTAAGAAACCGCGCAAAC
15	IE2	NUC SIG-2	CGCAAGAAGAAGAGCAAACGC

In Table 1, the abbreviation I/E refers to the intron/exon junction while the AUG region is the translation initiation region of IE2 mRNA whose transcription is controlled by the IE2 specific promoter region. The abbreviation "nuc sig" refers to nuclear localization signals of the IE2 protein.

Oligonucleotides or analogs useful in the invention are complementary to the DNA (especially for oligonucleotides directed to intron/exon junctions) or to the corresponding messenger RNA (mRNA) or pre-messenger RNA. Thus, the oligonucleotides and analogs in accordance with the invention preferably have one of the foregoing sequences or an effective portion thereof. Thus, it is preferred to employ any of these oligonucleotides (or their analogs) as set forth above or any of the similar nucleotides which persons of ordinary skill in the art can



prepare from knowledge of the preferred antisense targets for the modulation of the viral infection.

The oligonucleotides and oligonucleotide analogs of this invention can be used in diagnostics, therapeutics and as research reagents and kits. For therapeutic use, the oligonucleotide or oligonucleotide analog is administered to an animal suffering from a cytomegalovirus infection. It is generally preferred to apply the therapeutic agent in accordance with this invention internally such as intravenously, transdermally or intramuscularly. Other forms of administration such as topically or intralesionally may also be useful. Inclusion in suppositories is presently believed to be likely to be useful. Use of the oligonucleotides and oligonucleotide analogs of this invention in prophylaxis is also likely to be useful. Such may be accomplished, for example, by providing the medicament as a coating in condoms and the like. Use of pharmacologically acceptable carriers is also preferred for some embodiments.

The present invention is also useful in diagnostics and in research. Since the oligonucleotides and oligonucleotide analogs of this invention hybridize to nucleic acid from cytomegalovirus, sandwich and other assays can easily be constructed to exploit this fact. Provision of means for detecting hybridization of oligonucleotide or analog with cytomegalovirus present in a sample suspected of containing it can routinely be accomplished. Such provision may include enzyme conjugation, radiolabelling or any other suitable detection systems. Kits for detecting the presence or absence of cytomegalovirus may also be prepared.

#### EXAMPLES

##### EXAMPLE 1

Cells and Virus: Human foreskin fibroblast (ATCC #CRL 1635) cells used are obtained from the American Tissue Culture Collection. Cultures are grown in Dulbecco's Modified Eagle's Medium with 4.5 g/L glucose (high glucose DMEM) and supplemented with 10% fetal bovine serum (FBS), penicillin (100 units/ml), streptomycin (100 micrograms/ml)

and L-glutamine (2 mM). Stock cultures of human cytomegalovirus (HCMV strain AD169 or Towne) are grown on foreskin cells using low multiplicity infections (multiplicity of infection [MOI]=0.02 plaque forming units [PFU]/cell).

To assess the ability of oligonucleotides to inhibit CMV replication, an infectious yield assay will be used. To perform this assay, foreskin cells are seeded at a density of  $5 \times 10^5$  cells per well in Falcon 6 well tissue culture plates. Cells are overlaid with 2 ml of medium (high glucose DMEM with 10% FBS) and incubated at 37°C for 18-24 hours. Where appropriate, cells are overlaid with oligonucleotide preparations in 1 ml of medium at 24 hours after seeding the plates. Following an 18 hour incubation, all wells are rinsed with phosphate buffered saline and infected with HCMV at varying MOIs suspended in 0.5 ml of serum-free high glucose DMEM. Virus and cells are incubated at 37°C for 90 minutes on a rocking platform. Following viral adsorption, unadsorbed virus is rinsed away by washing with phosphate buffered saline. Where appropriate, 1 ml of medium (high glucose DMEM with 10% FBS) containing 10  $\mu$ M concentrations of oligonucleotide are added to the well and the cells are incubated for 4-5 days at 37°C. Control wells receive 1 ml of medium which contains no oligonucleotide.

Virus is harvested into the overlay medium and triplicate wells of each experimental point are combined. The suspension is frozen at -80°C. Virus titer is determined for each sample by plaque assay on human foreskin cell monolayers. Dilutions of each virus preparation are prepared and duplicate aliquots of each dilution are absorbed onto foreskin cells for 90 minutes with rocking. After adsorption, the unadsorbed virus inoculum is removed by rinsing the plates with phosphate buffered saline and the cells are overlaid with 2 ml of high glucose DMEM containing 5% FBS and 0.75% methyl cellulose. Cells are incubated at 37°C for 12-14 days before plaques are fixed with formalin, stained with crystal violet and counted. Plaque counts from treated

wells are compared with those from the control wells to establish the degree of inhibition of infectious virus production.

It is anticipated that treatment of CMV-infected cells with 10  $\mu$ M concentrations of phosphorothioate oligonucleotides which exhibit sequence complementarity to the CMV IE1, IE2 or DNA polymerase mRNAs will reduce the infectious yield of virus by 90%.

#### EXAMPLE 2

The mechanism of action of active CMV antisense compounds can also be validated. The molecular nature of any mechanism of action study is dictated by the CMV gene sequence which is the target of oligonucleotide inhibition. The most direct assays take advantage of the biological function of the protein encoded by the target CMV gene. The biological activity of an enzymatic protein often amplifies the end signal of such an assay so that the assay is very sensitive to even small changes in viral protein levels. Examples of CMV genes which are amenable to these types of assays are the DNA polymerase and IE1 & 2 loci.

For the DNA polymerase protein, a simple mechanistic assay involves assessing the ability of target specific oligonucleotides to inhibit the incorporation of  $^3$ H-thymidine into viral DNA under conditions which favor viral DNA polymerase activity over cellular DNA polymerase activity. The ability of the CMV IE proteins to transactivate RNA synthesis of certain CMV genes has been used to devise a transient gene expression assay, whose activity depends upon the presence of biologically active IE1 or IE2 proteins in an infected cell. Briefly, IE1 or IE2 responsive promoter regions are cloned 5' of an indicator gene (e.g., bacterial chloramphenicol acetyl transferase) CAT) in a plasmid vector. The vector is introduced into human foreskin cells, which in turn are infected with HCMV. The detection of CAT activity can be determined from cell lysates and CAT activity levels used to indirectly quantitate IE1 or IE2 protein levels. The effect of oligonucleotides on the CAT activity will be compared for both the IE1 and IE2 responsive constructs.

In cases in which an overt biological activity is not easily demonstrable, oligonucleotide-induced changes in protein levels can be determined by immunoprecipitation of infected cell proteins, gel electrophoresis of the immunoprecipitate in an SDS-acrylamide matrix, and detection of target protein levels by autoradiography of the gel. Proteins of assayable biological activity can also be quantitated by immunoprecipitation and gel electrophoretic techniques.

#### 10 **EXAMPLE 3**

The value of a CMV antisense drug will in a large degree depend on its ability to specifically interact with CMV RNA targets without adversely effecting host cell functions. Therefore it is important to evaluate the potential for nonspecific interactions and toxicities of active compounds. The potential for these adverse reactions is accessed in numerous models of acute and chronic cellular toxicity. Initially, active compounds are evaluated for toxicity in infected human foreskin cells using  $^3\text{H}$ -leucine and  $^3\text{H}$ -thymidine to measure effects on protein and DNA synthesis, respectively. From determinations of the oligonucleotide LD50 in these assays and the ID50 activity values obtained in the primary and secondary activity screens, a therapeutic index (T.I.) for each active oligonucleotide compound is determined. Only those compounds exhibiting T.I. more than 100 are then considered for subsequent evaluation.

#### **EXAMPLE 4**

Synthesis and characterization of oligonucleotides and analogs: Unmodified DNA oligonucleotides were synthesized on an automated DNA synthesizer (Applied Biosystems model 380B) using standard phosphoramidite chemistry with oxidation by iodine.  $\beta$ -cyanoethyl-diisopropyl-phosphoramidites were purchased from Applied Biosystems (Foster City, CA). For phosphorothioate oligonucleotides, the standard oxidation bottle was replaced by a 0.2 M solution of 3H-1,2-benzodithiole-3-one 1,1-dioxide in acetonitrile for the stepwise thiation of the phosphite

linkages. The thiation cycle wait step was increased to 68 seconds and was followed by the capping step.

2'-O-methyl phosphorothioate oligonucleotides were synthesized using 2'-O-methyl 8-cyanoethyldiisopropyl-  
5 phosphoramidites (Chemgenes, Needham MA) and the standard cycle for unmodified oligonucleotides, except the wait step after pulse delivery of tetrazole and base was increased to 360 seconds. The 3'-base used to start the synthesis was a 2'-deoxyribonucleotide.

10 After cleavage from the controlled pore glass column (Applied Biosystems) and deblocking in concentrated ammonium hydroxide at 55°C for 18 hours, the oligonucleotides were purified by precipitation twice out of 0.5 M NaCl with 2.5 volumes ethanol. Analytical gel  
15 electrophoresis was accomplished in 20% acrylamide, 8 M urea, 45 mM Tris-borate buffer, pH 7.0. Oligonucleotidedeoxy nucleotides and their phosphorothioate analogs were judged from electrophoresis to be greater than 80% full length material.

#### 20 **EXAMPLE 5**

ELISA assay for inhibition of HCMV replication by antisense oligonucleotides: Oligonucleotides complementary to human cytomegalovirus mRNA were tested for antiviral activity in an ELISA-based assay of HCMV replication. Normal human  
25 dermal fibroblasts (Clonetics Corp., San Diego CA) were grown in serum-free medium (Clonetics) and used to seed 96-well plates. When cells are approximately 80% confluent, they are pretreated with oligonucleotides. Approximately 20 hours after pretreatment the medium (containing  
30 oligonucleotides) is carefully poured off and the cells washed twice with warmed fibroblast basal medium (FBM, Clonetics). Cells are then infected with 100 µl/well of CMV stock diluted in FBM. The plates are incubated at 37°C for two hours. The medium (containing virus) is then  
35 carefully poured off and replaced with fresh, prewarmed FBM medium, 100µl per well. The plates are briefly incubated at 37°C and then 5 µl of oligonucleotide, diluted in FBM, is reintroduced into the medium in each well. Two days later, cells are post-treated again with oligonucleotides

in the same way. On day six, the plates are prepared for ELISA.

In preparation for ELISA, the medium is carefully poured off the plates, and cells are fixed in 200  $\mu$ l of absolute ethanol per well. Cells are fixed for 30 minutes at room temperature, then ethanol is removed and plates are air-dried. Plates are blocked for one hour prior to ELISA with PBS containing 2% BSA. Blocking solution is removed and 100  $\mu$ l of an anti-CMV antibody, diluted 1:2000 in PBS with 1% BSA, is added. Cells are incubated in antibody for one hour at 37°C and washed three times in PBS. The secondary antibody, biotinylated goat anti-mouse IgG (Bethesda Research Labs, MD), is diluted 1:1000 in PBS with 1% BSA, and incubated with cells for one hour at 37°C. Cells are then washed and incubated for one hour at 37°C in streptavidin-B-D-galactosidase. Color is developed with chlorophenol red-B-D-galactopyranoside, 20 mg dissolved in 10 ml of 50 mM Na Phosphate, 1.5 mM MgCl<sub>2</sub>; plates are shaken for 10 minutes and the absorbance is read at 575 nm.

Twenty-four oligonucleotides complementary to HCMV were tested for antiviral activity. The sequences and gene targets for these oligonucleotides are presented in Table 2.

TABLE 2

Oligonucleotide Analogs Tested for Activity Against HCMV

SEQ ID NO	ISIS #	Nucleotide #s	Target	Sequence	Type
1	2725		Nonsense	GTG TCA AGT GGC ACC ATA CG	P-S
2	2726		Nonsense	TGG AAA GTG TAC ACA GGC GAA	P-S
3	2728	80618-80639	DNA pol. AUG	GGG TTG AAA AAC ATA GCG GAC	P-S
4	2729	172755-172776	IE1 AUG	GAG GAC TCC ATC GTG TCA AG	P-S
5	2855	78445-78466	DNA pol. coding	GTG GGC CAT GAT GGA AGG	P-S
6	2856	77903-77924	DNA pol. coding	GTC CCG TAG ATG ACC CGC GCC	P-S
7	2869	78688-78709	DNA pol. coding	CGG CGC AGA TTG CAA GGG CGG	P-S
8	2870	78655-78676	DNA pol. coding	GCC GGA GCC GGG TGA AAC GCC	P-S
9	2871	77305-77326	DNA pol. coding	CGC CGT CCG GAC ACC GGG CGC	P-S
10	2876	77250-77271	DNA pol. coding	ACC GGG AAA CCA CGC CGG CGG	P-S
11	2877	77155-77176	DNA pol. coding	CCG CGC CCT CTT CTT TGC CGG	P-S
12	2882	173601-173622	IE1 int/exon 1	GGT ACT TAG GTC ACT CTT GGC	P-S
13	2883	172775-172796	IE1 int/exon 2	GAC GGT GAC TGC AGA AAA GAC	P-S
14	2884	172686-172707	IE1 int/exon 3	GAC ACG TAC CGT GGC ACC TTG	P-S
15	2890	172572-172592	IE1 int/exon 4	GTC TCG GCC CTA AAC ACA TG	P-S

-22-

16	2891	172387-172407	IE1 int/exon 5	CAG ACT TAC CGA CTT CTG CC	P-S
17	2908	172218-172238	IE1 int/exon 6	CTG TTT GAC TGT AGA GGA GG	P-S
18	2918	170373-170394	IE2 AUG	GGG TCC TTC ATC TGG GAG AGC	P-S
19	2919	170004-170025	IE2 int/exon 1	CGG CTC AGG TCG TCA ATC TTG	P-S
20	2920	169535-169556	IE2 int/exon 2	GGG CAC CAT GAC CTG TTT GGG	P-S
21	2921	170652-170673	IE2 nuc sig 1	GTT TTG CGC GGT TTC TTA CGC	P-S
22	2922	170120-170141	IE2 nuc sig 2	GCG TTT GCT CTT CTT CTT GCG	P-S
23	3245	173713-173734	IE1/IE2 5'cap	CGT CTC CAG GCG ATC TGA CGC	P-S
24	3246	173710-173731	IE1/IE2 5'cap	TGG CGT CTC CAG GCG ATC TGA	P-S
	3258	" "	" "	" "	2'-O-Me
	3300	" "	" "	" "	P-S/2'-O-Me
25	3224		Random	TCT GAG TAG CAG AGG AGC TC	P-S/2'-O-Me
26	3221		Random	CTC CAC GCG AAT TTT AAC ACA	P-S
	3266		" "	" "	2'-O-Me
27	1238		Random	ACT CGG GCT GCC ACT TGA CAG	P-S



Of the oligonucleotides tested, eight were complementary to mRNA encoding the HCMV DNA polymerase, and the remainder were complementary to RNA transcribed from the major immediate early promoter of HCMV. Since the two major protein products from this genomic region (IE1 and IE2) are synthesized from messenger RNA, which is transcribed from a common promoter, eight of these compounds are complementary to both the IE1 and IE2 mRNA. Three compound are complementary only to the IE1 and IE2 mRNA. Three compounds are complementary only to the IE1 mRNA, and the remaining five are specific for IE2 mRNA.

At a screening concentration of 5  $\mu$ M all but one compound showed some reduction of viral replication compared to untreated cells (Figures 1 and 2). Some compounds exhibited a markedly greater inhibition of virus replication than control oligonucleotides, and these were chosen for further characterization.

Dose-response experiments differentiated between non-specific effects and sequence-specific inhibition of HCMV replication by antisense oligonucleotides. Compounds ISIS 2922 (SEQ ID NO: 22), ISIS 2882 (SEQ ID NO: 12), ISIS 2918 (SEQ ID NO: 18), ISIS 2919 (SEQ ID NO: 19) and ISIS 3300 (SEQ ID NO: 24, P=S/2'-O-Me) all showed inhibition of HCMV replication at lower doses than randomized oligonucleotides with no complementarity to HCMV (Figure 3). Compounds ISIS 2918 (SEQ ID NO: 18), ISIS 2919 (SEQ ID NO: 19), and ISIS 2922 (SEQ ID NO: 22) are complementary to IE2 RNA sequences. ISIS 2882 (SEQ ID NO: 12) and ISIS 3300 (SEQ ID NO: 24, P=S and 2'-O-Me) are complementary to the 5' cap region of IE1 and IE2 transcripts. Except where indicated in Table 2, oligonucleotides used are phosphorothioates; ISIS 3300 contains 2'-O-methyl-modified nucleosides with phosphorothioate linkages. This double modification was shown to convey much stronger antiviral activity upon the oligonucleotide than either the phosphorothioate (ISIS 3246, moderate activity) or the 2'-O-methyl modification (ISIS 3258, slight activity) alone. The activity of ISIS 2919 and ISIS 2922 relative to a

randomized control oligonucleotide was confirmed in an independent dose-response experiment (Figure 4).

- 25 -

## SEQUENCE LISTING

## (1) GENERAL INFORMATION:

- (i) APPLICANT: Anderson, Kevin P.  
Draper, Kenneth G.
- 5 (ii) TITLE OF INVENTION: Oligonucleotides for  
Modulating the Effects of Cytomegalovirus Infections
- (iii) NUMBER OF SEQUENCES: 27
- (iv) CORRESPONDENCE ADDRESS:
- (A) ADDRESSEE: Woodcock Washburn Kurtz Mackiewicz  
10 & Norris
- (B) STREET: One Liberty Place -- 46th floor
- (C) CITY: Philadelphia
- (D) STATE: PA
- (E) COUNTRY: USA
- 15 (F) ZIP: 19103
- (v) COMPUTER READABLE FORM:
- (A) MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb
- STORAGE
- (B) COMPUTER: IBM PS/2
- 20 (C) OPERATING SYSTEM: PC-DOS
- (D) SOFTWARE: WORDPERFECT 5.0
- (vi) CURRENT APPLICATION DATA:
- (A) APPLICATION NUMBER: n/a
- (B) FILING DATE: herewith
- 25 (C) CLASSIFICATION:
- (viii) ATTORNEY/AGENT INFORMATION:
- (A) NAME: Licata, Jane M.
- (B) REGISTRATION NUMBER: 32,257
- (C) REFERENCE/DOCKET NUMBER: ISIS-0408
- 30 (ix) TELECOMMUNICATION INFORMATION:
- (A) TELEPHONE: (215) 568-3100
- (B) TELEFAX: (215) 568-3439

## (2) INFORMATION FOR SEQ ID NO:1:

- (i) SEQUENCE CHARACTERISTICS:
- 35 (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single

SUBSTITUTE SHEET

- 26 -

- (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: DNA (genomic)
- (iii) HYPOTHETICAL: NO
- (iv) ANTI-SENSE: YES
- 5 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:  
GTGTCAAGTG GCACCATACG 20
- (2) INFORMATION FOR SEQ ID NO:2:
- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 21 base pairs
- 10 (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: DNA (genomic)
- (iii) HYPOTHETICAL: NO
- 15 (iv) ANTI-SENSE: YES
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:  
TGGAAAGTGT ACACAGGCGA A 21
- (2) INFORMATION FOR SEQ ID NO:3:
- (i) SEQUENCE CHARACTERISTICS:
- 20 (A) LENGTH: 21 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: DNA (genomic)
- 25 (iii) HYPOTHETICAL: NO
- (iv) ANTI-SENSE: YES
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:  
GGGTTGAAAA ACATAGCGGA C 21
- (2) INFORMATION FOR SEQ ID NO:4:
- 30 (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear
- 35 (ii) MOLECULE TYPE: DNA (genomic)
- (iii) HYPOTHETICAL: NO

SUBSTITUTE SHEET

- 27 -

(iv) ANTI-SENSE: YES

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

GAGGACTCCA TCGTGTCAAG

20

(2) INFORMATION FOR SEQ ID NO:5:

5 (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 21 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

10 (ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: YES

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

GTGGGCCATG ATGATGGAAG G

21

15 (2) INFORMATION FOR SEQ ID NO:6:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 21 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

20 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: YES

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

25 GTCCCGTAGA TGACCCGCGC C

21

(2) INFORMATION FOR SEQ ID NO:7:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 21 base pairs

(B) TYPE: nucleic acid

30 (C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: YES

35 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

CURSTITITF SHEET

- 28 -

CGGCGCAGAT TGCAAGGGCG G

21

## (2) INFORMATION FOR SEQ ID NO:8:

## (i) SEQUENCE CHARACTERISTICS:

- 5 (A) LENGTH: 21 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

10 (iv) ANTI-SENSE: YES

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

GCCGGAGCCG GGTGAAACGC C

21

## (2) INFORMATION FOR SEQ ID NO:9:

## (i) SEQUENCE CHARACTERISTICS:

- 15 (A) LENGTH: 21 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

20 (iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: YES

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:

CGCCGTCCGG ACACCGGGCG C

21

## (2) INFORMATION FOR SEQ ID NO:10:

## 25 (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 21 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

30 (ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: YES

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:

ACCGGGAAC CACGCCGGCG G

21

## 35 (2) INFORMATION FOR SEQ ID NO:11:

SUBSTITUTE SHEET

- 29 -

## (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 21 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

5 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: YES

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:

10 CCGCGCCCTC TTCTTTGCCG G

21

## (2) INFORMATION FOR SEQ ID NO:12:

## (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 21 base pairs

(B) TYPE: nucleic acid

15 (C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: YES

20 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:

GGTACTTACG TCACTCTTGG C

21

## (2) INFORMATION FOR SEQ ID NO:13:

## (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 21 base pairs

25 (B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

30 (iv) ANTI-SENSE: YES

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:

GACGGTGACT GCAGAAAAGA C

21

## (2) INFORMATION FOR SEQ ID NO:14:

## (i) SEQUENCE CHARACTERISTICS:

35 (A) LENGTH: 21 base pairs

(B) TYPE: nucleic acid

- 30 -

- (C) STRANDEDNESS: single  
(D) TOPOLOGY: linear  
(ii) MOLECULE TYPE: DNA (genomic)  
(iii) HYPOTHETICAL: NO  
5 (iv) ANTI-SENSE: YES  
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:  
GACACGTACC GTGGCACCTT G 21

- (2) INFORMATION FOR SEQ ID NO:15:  
(i) SEQUENCE CHARACTERISTICS:  
10 (A) LENGTH: 20 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear  
(ii) MOLECULE TYPE: DNA (genomic)  
15 (iii) HYPOTHETICAL: NO  
(iv) ANTI-SENSE: YES  
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:  
GTCTCGGGCC TAAACACATG 20

- (2) INFORMATION FOR SEQ ID NO:16:  
20 (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 20 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear  
25 (ii) MOLECULE TYPE: DNA (genomic)  
(iii) HYPOTHETICAL: NO  
(iv) ANTI-SENSE: YES  
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:16:  
CAGACTTACC GACTTCTGCC 20

- 30 (2) INFORMATION FOR SEQ ID NO:17:  
(i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 20 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
35 (D) TOPOLOGY: linear  
(ii) MOLECULE TYPE: DNA (genomic)

SUBSTITUTE SHEET



- 31 -

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: YES

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:17:

CTGTTTGA CT TAGAGGAGG

20

5 (2) INFORMATION FOR SEQ ID NO:18:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 21 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

10 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: YES

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:18:

15 GGGTCCTTCA TCTGGGAGAG C

21

(2) INFORMATION FOR SEQ ID NO:19:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 21 base pairs

(B) TYPE: nucleic acid

20 (C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: YES

25 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:19:

CGGCTCAGGT CGTCAATCTT G

21

(2) INFORMATION FOR SEQ ID NO:20:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 21 base pairs

30 (B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

35 (iv) ANTI-SENSE: YES

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:20:

SUBSTITUTE SHEET

GCGCACCATG ACCTGTTTGG G

21

## (2) INFORMATION FOR SEQ ID NO:21:

## (i) SEQUENCE CHARACTERISTICS:

- 5 (A) LENGTH: 21 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

10 (iv) ANTI-SENSE: YES

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:21:

GTTTTGCGCG GTTCTTACG C

21

## (2) INFORMATION FOR SEQ ID NO:22:

## (i) SEQUENCE CHARACTERISTICS:

- 15 (A) LENGTH: 21 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

20 (iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: YES

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:22:

GCGTTTGCTC TTCTTCTTGC G

21

## (2) INFORMATION FOR SEQ ID NO:23:

## 25 (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 21 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

30 (ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: YES

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:23:

CGTCTCCAGG CGATCTGACG C

21

- 33 -

## (2) INFORMATION FOR SEQ ID NO:24:

## (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 21 base pairs

(B) TYPE: nucleic acid

5 (C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: YES

10 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:24:

TGGCGTCTCC AGGCGATCTG A

21

## (2) INFORMATION FOR SEQ ID NO:25:

## (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20 base pairs

15 (B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

20 (iv) ANTI-SENSE: YES

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:25:

TCTGAGTAGC AGAGGAGCTC

20

## (2) INFORMATION FOR SEQ ID NO:26:

## (i) SEQUENCE CHARACTERISTICS:

25 (A) LENGTH: 21 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

30 (iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: YES

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:26:

CTCCACGCGA ATTTTAACAC A

21

## (2) INFORMATION FOR SEQ ID NO:27:

35 (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 21 base pairs

SUBSTITUTE SHEET

- 34 -

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

5 (iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: YES

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:27:

ACTCGGGCTG CCACTTGACA G

21

## CLAIMS

## What is claimed is

1. An oligonucleotide or oligonucleotide analog specifically hybridizable with at least a portion of RNA or DNA deriving from IE1, IE2 or DNA polymerase genes of a cytomegalovirus.
2. The oligonucleotide or oligonucleotide analog of claim 1 specifically hybridizable with at least a portion of the mRNA cap site, the AUG region, the conserved amino acid region, or the CMV insertion regions between bases 608-697 or 1109-1159 of the DNA polymerase gene.
3. The oligonucleotide or oligonucleotide analog of claim 1 specifically hybridizable with at least a portion of the mRNA cap site, the AUG region or an intron/exon junction region of the IE1 gene.
4. The oligonucleotide or oligonucleotide analog of claim 1 specifically hybridizable with at least a portion of the AUG/CAP site, the AUG region, an IE2 specific intron/exon junction region, or a nuclear location signal region of the IE2 gene.
5. The oligonucleotide or oligonucleotide analog of claim 1 in a pharmaceutically acceptable carrier.
6. The oligonucleotide or oligonucleotide analog of claim 1 having from 5 to about 50 nucleic acid base units.
7. The oligonucleotide or oligonucleotide analog of claim 1 having from 8 to about 25 nucleic acid base units.
8. The oligonucleotide or oligonucleotide analog of claim 1 having from 12 to about 25 nucleic acid base units.
9. The oligonucleotide or oligonucleotide analog of claim 1 wherein at least some of the linking groups between nucleotide units of the oligonucleotide comprise sulfur-containing species.
10. The oligonucleotide or oligonucleotide analog of claim 1 wherein at least some of the linking

groups between nucleotide units of the oligonucleotide comprise phosphorothioate moieties.

11. An oligonucleotide or oligonucleotide analog complementary to the DNA or corresponding RNA or pre-messenger RNA of at least a portion of one of the sequences:

10 GGA CCG GGA CCA CCG TCG TC,  
GTC CGC TAT GTT TTT CAA CCC,  
CCT TCC ATC ATC ATG GCC CAC,  
GGC GCG GGT CAT CTA CGG GAC,  
CCG CTG TGC CCG GCG ACG CGG  
CCG CCC TTG CAA TCT GCG CCG  
GGC GTT TCA CCC GGC TCC GGC,  
15 GCG CCC GGT GTC CGG ACG GCG  
CCG CCG GCG TGG TTT CCC GGT  
CCG GCA AAG AAG AGG GCG CGG,  
GTG AAC CGT CAG ATC GCC TGG,  
CTT GAC ACG ATG GAG TCC TC,  
GCC AAG AGT GAC GTA AGT ACC,  
20 GTC TTT TCT GCA GTC ACC GTC,  
CAA GGT GCC ACG GTA CGT GTC,  
CAT GTG TTT AGG CCC GAG AC,  
GGC AGA ACT CGG TAA GTC TG,  
CCT CCT CTA CAG TCA AAC AG;  
25 GCG CCT ATC ATG CTG CCC CTC,  
GCT CTC CCA GAT GAA CCA CCC,  
CAA GAT TGA CGA GGT GAG CCG,  
CCC AAA CAG GTC ATG GTG CGC,  
GCG TAA GAA ACC GCG CAA AAC, or  
30 CGC AAG AAG AAG AGC AAA CGC.

12. The oligonucleotide or oligonucleotide analog of claim 11 in a pharmaceutically acceptable carrier.

13. The oligonucleotide or oligonucleotide analog of claim 11 wherein at least some of the linking groups between nucleotide units of the oligonucleotide comprise sulfur-containing species.

5 14. The oligonucleotide or oligonucleotide analog of claim 11 wherein at least some of the linking groups between nucleotide units of the oligonucleotide comprise phosphorothioate moieties.

10 15. A method for modulating the activity of a cytomegalovirus infection comprising contacting an animal suspected of having a CMV infection with an oligonucleotide or oligonucleotide analog specifically hybridizable with at least a portion of RNA or DNA deriving from IE1, IE2 or DNA polymerase genes of the cytomegalovirus.

15 16. The method of claim 15 wherein said infection is by human cytomegalovirus.

17. The method of claim 15 wherein the oligonucleotide or oligonucleotide analog is specifically hybridizable with at least a portion of the mRNA cap site, 20 the AUG region, the conserved amino acid region, the CMV insertion regions between bases 608-697 or 1109-1159 of the DNA polymerase gene.

18. The method of claim 15 wherein the oligonucleotide or oligonucleotide analog is specifically 25 hybridizable with at least a portion of the mRNA cap site, the AUG region or an intron/exon junction region of the IE1 gene.

19. The method of claim 15 wherein the oligonucleotide or oligonucleotide analog is specifically 30 hybridizable with at least a portion of the AUG/CAP site, the AUG region, an IE2 specific intron/exon junction region, or a nuclear location signal region of the IE2 gene.

20. The method of claim 15 wherein the 35 oligonucleotide or oligonucleotide analog is in a pharmaceutically acceptable carrier.

21. The method of claim 15 wherein the oligonucleotide or oligonucleotide analog of claim 1 has from 5 to about 50 nucleic acid base units.

22. The method of claim 15 wherein the oligonucleotide or oligonucleotide analog of claim 1 has from 8 to about 25 nucleic acid base units.

23. The method of claim 15 wherein the  
5 oligonucleotide or oligonucleotide analog of claim 1 has from 12 to about 25 nucleic acid base units.

24. The method of claim 15 wherein at least some of the linking groups between nucleotide units of the oligonucleotide comprise sulfur-containing species.

10 25. The method of claim 15 wherein at least some of the linking groups between nucleotide units of the oligonucleotide comprise phosphorothioate moieties.

26. A method for modulating the activity of a cytomegalovirus infection comprising contacting an animal  
15 suspected of having a CMV infection with an oligonucleotide or oligonucleotide analog complementary to the DNA or corresponding RNA or pre-messenger RNA of at least a portion of one of the sequences:

GGA CCG GGA CCA CCG TCG TC,  
20 GTC CGC TAT GTT TTT CAA CCC,  
CCT TCC ATC ATC ATG GCC CAC,  
GGC GCG GGT CAT CTA CGG GAC,  
CCG CTG TGC CCG GCG ACG CGG  
CCG CCC TTG CAA TCT GCG CCG  
25 GGC GTT TCA CCC GGC TCC GGC,  
GCG CCC GGT GTC CGG ACG GCG  
CCG CCG GCG TGG TTT CCC GGT  
CCG GCA AAG AAG AGG GCG CGG,  
GTG AAC CGT CAG ATC GCC TGG,  
30 CTT GAC ACG ATG GAG TCC TC,  
GCC AAG AGT GAC GTA AGT ACC,  
GTC TTT TCT GCA GTC ACC GTC,  
CAA GGT GCC ACG GTA CGT GTC,  
CAT GTG TTT AGG CCC GAG AC,  
35 GGC AGA ACT CGG TAA GTC TG,



- 39 -

CCT CCT CTA CAG TCA AAC AG,  
GCG CCT ATC ATG CTG CCC CTC,  
GCT CTC CCA GAT GAA CCA CCC,  
CAA GAT TGA CGA GGT GAG CCG,  
5 CCC AAA CAG GTC ATG GTG CGC,  
GCG TAA GAA ACC GCG CAA AAC, or  
CGC AAG AAG AAG AGC AAA CGC.

27. An oligonucleotide or oligonucleotide analog specifically hybridizable with the DNA or corresponding  
10 mRNA or pre-mRNA of cytomegalovirus comprising at least a portion of one of the sequences identified in Table 2.

28. The oligonucleotide or oligonucleotide analog of claim 27 in a pharmaceutically acceptable carrier.

29. The oligonucleotide or oligonucleotide analog of  
15 claim 27 wherein at least some of the linking groups between nucleotide units of the oligonucleotide comprise sulfur-containing species.

30. The oligonucleotide or oligonucleotide analog of claim 27 wherein at least some of the linking groups  
20 between nucleotide units of the oligonucleotide comprise phosphorothioate moieties.

31. The oligonucleotide or oligonucleotide analog of claim 27 wherein at least some of the nucleotide bases have  
2'-O-alkyl modifications.

25 32. The oligonucleotide or oligonucleotide analog of claim 31 wherein the modified bases are 2'-O-methyls.

33. A method for modulating the activity of a cytomegalovirus infection comprising contacting an animal suspected of having a cytomegalovirus infection with a  
30 therapeutically effective amount of an oligonucleotide or oligonucleotide analog specifically hybridizable with the DNA or corresponding mRNA or pre-mRNA of cytomegalovirus comprising at least a portion of one of the sequences identified in Table 2.

35 34. The method of claim 33 wherein the oligonucleotide or oligonucleotide analog is in a pharmaceutically acceptable carrier.

**SUBSTITUTE SHEET**

35. The method of claim 33 wherein at least some of the linking groups between nucleotide units of the oligonucleotide comprise sulfur-containing species.

5 36. The method of claim 33 wherein at least some of the linking groups between nucleotide units of the oligonucleotide comprise phosphorothioate moieties.


37. The method of claim 33 wherein at least some of the nucleotide bases of the oligonucleotide have 2'-O-alkyl modifications.

10 38. The method of Claim 37 wherein the modified bases are 2'-O-methyls.


39. The oligonucleotide or oligonucleotide analog of claim 27 comprising 2'-O-methyl-modified nucleosides with phosphorothioate linkages.

15 40. The method of claim 33 wherein said oligonucleotide comprises 2'-O-methyl-modified nucleosides with phosphorothioate linkages.

1/4

**Fig. 1**


2/4

***Fig. 2***


SUBSTITUTE SHEET

3/4

- ▣ 1238
- ◆ 2918
- 2919
- ◇ 2922
- 2882
- 2856
- ▲ 3224
- △ 3300

***Fig. 3***

4/4

***Fig. 4***

# INTERNATIONAL SEARCH REPORT

International Application No. PCT/US91/05815

<b>I. CLASSIFICATION OF SUBJECT MATTER</b> (if several classification symbols apply, indicate all) <sup>6</sup>		
According to International Patent Classification (IPC) or to both National Classification and IPC IPC(5): 007H 15/12, 17/00; C12Q 1/68; C12P 19/34; C12N 15/00; A 01N 43/04; A61K 31/70 U.S. CL: 536/27, 28, 29; 435/6, 91, 172.3; 514/44		
<b>II. FIELDS SEARCHED</b>		
Minimum Documentation Searched <sup>7</sup>		
Classification System	Classification Symbols	
U.S.	536/27, 28, 29; 435/6, 91, 172.3; 514/44	
Documentation Searched other than Minimum Documentation to the extent that such Documents are included in the Fields Searched <sup>8</sup>		
Databases: Online Sequence Search, Genbank/EMBL Automated Patent System (File USPAT 1971-1991)		
<b>III. DOCUMENTS CONSIDERED TO BE RELEVANT</b> <sup>9</sup>		
Category <sup>9</sup>	Citation of Document, <sup>11</sup> with indication, where appropriate, of the relevant passages <sup>12</sup>	Relevant to Claim No. <sup>13</sup>
Y	Pharmaceutical Research, Vol. 5, No. 9, issued 1988, Gerald Zon, "Oligonucleotide Analogues as Potential Chemotherapeutic Agents", pages 539-549, see the entire article.	1-40
Y	Journal of Virology, Vol. 49, No. 1, issued January 1984, Stenberg et al., "Structural Analysis of the Major Immediate Early Gene of Human Cytomegalovirus", pages 190-199, see especially page 198, Fig. 8.	1-40
<div style="display: flex; justify-content: space-between;"> <div style="width: 48%;"> <p><sup>10</sup> Special categories of cited documents:</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> </div> <div style="width: 48%;"> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</p> <p>"A" document member of the same patent family</p> </div> </div>		
<b>IV. CERTIFICATION</b>		
Date of the Actual Completion of the International Search	Date of Mailing of this International Search Report	
20 SEPTEMBER 1991	28 OCT 1991	
International Searching Authority	Signature of Authorized Officer	
ISA/US	<div style="display: flex; align-items: center;"> <div style="margin-right: 10px;">GIAN WANG</div> </div>	

**FURTHER INFORMATION CONTINUED FROM THE SECOND SHEET**

Y	Journal of Virology, Vol. 56, No.3, issued December 1985, Stenberg et al., "Multiple Spliced and Unspliced Transcripts from Human Cytomegalovirus Immediate-Early Region 2 and Evidence for a Common Initiation Site Within Immediate-Early Region 1", pages 665-675, see especially page 668, Fig.3.	1-40
---	---	------

**V. ☐ OBSERVATIONS WHERE CERTAIN CLAIMS WERE FOUND UNSEARCHABLE <sup>1</sup>**

This International search report has not been established in respect of certain claims under Article 17(2) (a) for the following reasons:

1. ☐ Claim numbers ..... because they relate to subject matter <sup>12</sup> not required to be searched by this Authority, namely:
  
2. ☐ Claim numbers ..... because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out <sup>12</sup>, specifically:
  
3. ☐ Claim numbers ..... because they are dependent claims not drafted in accordance with the second and third sentences of PCT Rule 6.4(a).

**VI. ☐ OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING <sup>2</sup>**

This International Searching Authority found multiple inventions in this international application as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims of the international application.
2. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims of the international application for which fees were paid, specifically claims:
  
3. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claim numbers:
  
4. ☐ As all searchable claims could be searched without effort justifying an additional fee, the International Searching Authority did not invite payment of any additional fee.

**Remark on Protest**

- ☐ The additional search fees were accompanied by applicant's protest.  
☐ No protest accompanied the payment of additional search fees.



## III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)

Category *	Citation of Document, with indication, where appropriate, of the relevant passages	Relevant to Claim No
Y	Journal of Virology, Vol.61, No.1, issued January 1987, Kouzarides et al., "Sequence and Transcription Analysis of the Human Cytomegalovirus DNA Polymerase Gene", pages 125-133, see especially page 128, Fig.2	1-40
Y	The EMBO Journal, Vol.5, No.11, issued 1986, Cranage et al., "Identification of the human Cytomegalovirus Glycoprotein B Gene and Induction of Neutralizing Antibodies via its Expression in Recombinant Vaccinia Virus", pages 3057-3063, see especially page 3058, Fig. 1.	1-40
Y	Virology, Vol.167, issued 1988, Spaete et al., "Human Cytomegalovirus Strain Towne Glycoprotein B is Processed by Proteolytic Cleavage", pages 207-225, see especially pages 212-213, Fig. 2.	1-40

This Page Blank (uspto)

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☒ **BLACK BORDERS**
- ☒ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☒ **FADED TEXT OR DRAWING**
- ☒ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☒ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☒ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**

**THIS PAGE BLANK (USPTO)**